Type 1 Diabetes vs Type 2 Diabetes: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00961 | 0.0081 | 0.0114 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00213 | 0.00171 | 0.00264 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00748 | 0.00589 | 0.00932 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 4.52 | 3.42 | 5.97 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 4.56 | 3.45 | 6.02 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more participant with a serious adverse event on Type 1 Diabetes than on Type 2 Diabetes | 134 | 107 | 170 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Type 1 Diabetes | Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment. | 130 | 13,529 | EG000 | ClinicalTrials.gov |
| Group 2 | Type 2 Diabetes | Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment. | 80 | 37,641 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, serious adverse events | ClinicalTrials.gov |
| Time frame | Over 3, 6 and 12 months, respectively, depending on the participating country | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Observational Study to Evaluate the Safety of Levemir® in Diabetes | ClinicalTrials.gov |
| NCT number | NCT00659295 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | insulin detemir | ClinicalTrials.gov |
| Lead sponsor | Novo Nordisk A/S | ClinicalTrials.gov |
| Results first posted | 2011-08-16 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00659295?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.